Table 1 Eligibility criteria for study selection
From: Proteomics for heart failure risk stratification: a systematic review
Category | Inclusion criteria | Exclusion criteria |
|---|---|---|
Population | • Human • Adults (aged ≥ 18 years) with HF irrespective of EF | • Non-human studies • Children and adolescents (aged 2–17 years) • Adults without HF |
Measurement(s)/exposure(s) | • Assessed the plasma or serum proteome • Proteins measured by high-throughput affinity-based proteomic techniques including aptamer-based (SomaScan) or antibody-based (Olink) | • Assessed biological proteome other than plasma or serum • Proteomic techniques other than the large-scale affinity platforms |
Comparator/association(s) | • Reported protein association with outcomes | • No protein association with outcomes reported |
Outcome(s) | • All-cause death • Cardiovascular death • A composite outcome that includes death | • Absence of death outcomes |
Study design(s) | • Observational studies (all types, e.g., cohort, case–control, cross-sections, longitudinal, prospective, retrospective) • Clinical trials | • Articles without primary data (commentaries, editorials, protocols, letters, reviews of all types) • Incomplete data (conference abstracts/proceedings) |
Language | • No restrictions | • NA |
Date of publication | • 2012 to June 2023 | • Before 2012 |